Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus
Creators
- 1. Vaccine Branch, National Cancer Institute, National Institutes of Health, Bldg. 10-Rm 6B-09, NIH, Bethesda, MD 20892-1578 (United States) and Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (United States)
- 2. Vaccine Branch, National Cancer Institute, National Institutes of Health, Bldg. 10-Rm 6B-09, NIH, Bethesda, MD 20892-1578 (United States)
- 3. W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (United States)
- 4. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 (United States)
Description
Natural infection and vaccination with a live-attenuated measles virus (MV) induce CD8+ T-cell-mediated immune responses that may play a central role in controlling MV infection. In this study, we show that newly identified human HLA-A2 epitopes from MV hemagglutinin (H) and fusion (F) proteins induced protective immunity in HLA-A2 transgenic mice challenged with recombinant vaccinia viruses expressing F or H protein. HLA-A2 epitopes were predicted and synthesized. Five and four peptides from H and F, respectively, bound to HLA-A2 molecules in a T2-binding assay, and four from H and two from F could induce peptide-specific CD8+ T cell responses in HLA-A2 transgenic mice. Further experiments proved that three peptides from H (H9-567, H10-250, and H10-516) and one from F protein (F9-57) were endogenously processed and presented on HLA-A2 molecules. All peptides tested in this study are common to 5 different strains of MV including Edmonston. In both A2Kb and HHD-2 mice, the identified peptide epitopes induced protective immunity against recombinant vaccinia viruses expressing H or F. Because F and H proteins induce neutralizing antibodies, they are major components of new vaccine strategies, and therefore data from this study will contribute to the development of new vaccines against MV infection
Additional details
Identifiers
- DOI
- 10.1016/j.virol.2006.04.040;
- PII
- S0042-6822(06)00304-7;
Publishing Information
- Journal Title
- Virology
- Journal Volume
- 352
- Journal Issue
- 2
- Journal Page Range
- p. 390-399
- ISSN
- 0042-6822
- CODEN
- VIRLAX
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 38021015
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ANTIBODIES; IMMUNITY; LYMPHOCYTES; MEASLES; MEASLES VIRUS; PEPTIDES; TRANSGENIC MICE; VACCINES; VACCINIA VIRUS
- Descriptors DEC
- ANIMAL CELLS; ANIMALS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; CONNECTIVE TISSUE CELLS; DISEASES; INFECTIOUS DISEASES; LEUKOCYTES; MAMMALS; MATERIALS; MICE; MICROORGANISMS; ORGANIC COMPOUNDS; PARASITES; PROTEINS; RODENTS; SOMATIC CELLS; TRANSGENIC ANIMALS; VERTEBRATES; VIRAL DISEASES; VIRUSES
Optional Information
- Copyright
- Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved.